These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18767892)

  • 1. NICE Guide to the Methods of Technology Appraisal: pharmaceutical industry perspective.
    Earnshaw J; Lewis G
    Pharmacoeconomics; 2008; 26(9):725-7. PubMed ID: 18767892
    [No Abstract]   [Full Text] [Related]  

  • 2. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

  • 3. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
    Birch S; Gafni A
    Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
    [No Abstract]   [Full Text] [Related]  

  • 4. Technology assessment in the German context.
    Drummond M
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S3. PubMed ID: 17619919
    [No Abstract]   [Full Text] [Related]  

  • 5. Searching for a threshold - Not so NICE..
    Mooney G; Coast J; Jan S; ; Ryan M; Wiseman V
    J Health Serv Res Policy; 2007 Jul; 12(3):190; author reply 190-1. PubMed ID: 17716427
    [No Abstract]   [Full Text] [Related]  

  • 6. Using health outcomes data to inform decision-making: government agency perspective.
    Taylor R
    Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipodean assessment. Activities, actions, and achievements.
    Mitchell AS
    Int J Technol Assess Health Care; 2002; 18(2):203-12. PubMed ID: 12053421
    [No Abstract]   [Full Text] [Related]  

  • 8. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug prices and value for money: the Australian Pharmaceutical Benefits Scheme.
    Henry DA; Hill SR; Harris A
    JAMA; 2005 Nov; 294(20):2630-2. PubMed ID: 16304078
    [No Abstract]   [Full Text] [Related]  

  • 10. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of the appraisal function of the National Institute for Clinical Excellence (NICE).
    Buxton M
    Value Health; 2001; 4(3):212-6. PubMed ID: 11705183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [More care for a limited budget; a case for a better use of the efficiency criteria].
    Rutten FF; Brouwer WB
    Ned Tijdschr Geneeskd; 2002 Nov; 146(47):2254-8. PubMed ID: 12481524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A national drug agency.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    CMAJ; 2003 Apr; 168(8):962-3. PubMed ID: 12695372
    [No Abstract]   [Full Text] [Related]  

  • 15. We need Romanow's National Drug Agency.
    CMAJ; 2003 Feb; 168(3):249, 251. PubMed ID: 12566321
    [No Abstract]   [Full Text] [Related]  

  • 16. NICE Methodology for Technology Appraisals: cutting edge or tried and trusted?
    Longworth L; Longson C
    Pharmacoeconomics; 2008; 26(9):729-32. PubMed ID: 18767893
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The South African Guidelines for Pharmacoeconomic Submissions' Evidence Requirements Compared with Other African Countries and The National Institute for Health and Care Excellence in England.
    Marsh SE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2020 Apr; 20(2):155-168. PubMed ID: 31056961
    [No Abstract]   [Full Text] [Related]  

  • 19. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion.
    Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J
    Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NICE reference case requirement: more pain for what, if any, gain?
    Gafni A; Birch S
    Pharmacoeconomics; 2004; 22(4):271-3. PubMed ID: 14974877
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.